For decades, artificial intelligence advanced in careful, mostly linear steps. Researchers built models. Engineers improved performance. Organizations deployed systems to automate specific tasks. Each ...
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Welcome to the era of "Action Drift," where your agents are negotiating trades your CRO won’t understand for another six ...
Explore RNA interference methods, comparing siRNA and shRNA for gene knockdown, their mechanisms, advantages, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback